Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognoses

25 Jan 2023

Abstract excerpt

BRAF mutations are the oncogenic drivers in colorectal cancer and V600 mutations (Class1), which lead to RAS-independent active monomers, are the most common mutation types. BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed the mutational profiles of 328 treatment-naïve colorectal tumors with BRAF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Genetic factors in colorectal cancer
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36694231
DOI: 10.1186/s40364-022-00443-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical and genomic distinctions of Class1/2/3 BRAF-mutant colorectal cancer and differential prognosesPMID 36694231Read ↗

Clinical features and mutation analysis of class 1/2/3 BRAF mutation colorectal cancer.Semantic proximity Read ↗

Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis.Semantic proximity Read ↗

Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database.Semantic proximity Read ↗

BRAF Mutations as Actionable Targets: A Paradigm Shift in the Management of Colorectal Cancer and Novel Avenues.Semantic proximity Read ↗

Distinct clinical and genomic profiles of braf mutation subtypes in Chinese colorectal cancer: a retrospective cohort study with cross-population validation.Semantic proximity Read ↗

Improvements in Clinical Outcomes for BRAFV600E -Mutant Metastatic Colorectal Cancer.Semantic proximity Read ↗

European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer.Semantic proximity Read ↗

The clinical, genomic, and transcriptomic landscape of BRAF mutant cancersSemantic proximity Read ↗

The Evolving Role of Consensus Molecular Subtypes: a Step Beyond Inpatient Selection for Treatment of Colorectal Cancer.Semantic proximity Read ↗

Consensus molecular subtypes of colorectal cancer in clinical practice: A translational approachSemantic proximity Read ↗

Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer.Semantic proximity Read ↗

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.